Michael Adamzik1,2, Ulrich H Frey3,4, Kathrin Rieman3, Stephan Sixt4, Martin Beiderlinden4, Winfried Siffert3, Jürgen Peters4. 1. Institut für Pharmakogenetik, University Hospital Essen, University of Duisburg-Essen, Hufelandstrasse 55, 45147, Essen, Germany. Michael.adamzik@uni-duisburg-essen.de. 2. Klinik für Anästhesiologie und Intensivmedizin, University Hospital Essen, University of Duisburg-Essen, Hufelandstrasse 55, 45147, Essen, Germany. Michael.adamzik@uni-duisburg-essen.de. 3. Institut für Pharmakogenetik, University Hospital Essen, University of Duisburg-Essen, Hufelandstrasse 55, 45147, Essen, Germany. 4. Klinik für Anästhesiologie und Intensivmedizin, University Hospital Essen, University of Duisburg-Essen, Hufelandstrasse 55, 45147, Essen, Germany.
Abstract
OBJECTIVE: This study investigated whether the insertion/deletion polymorphism in the promoter of NFKB1 is associated with severity and/or mortality in ARDS. DESIGN AND SETTING: Prospective study in a mixed anesthesiological ICU of the University Hospital Essen. PATIENTS AND PARTICIPANTS: 103 adult patients with ARDS (white Germans). MEASUREMENTS AND RESULTS: Patients with ARDS were genotyped for the insertion/deletion polymorphism in the promoter of NFKB1 (-94ins/delATTG). In ARDS patients genotypes differed significantly between those with severe ARDS [Lung Injury Score (LIS)>or=3; 23 homozygote deletion (DD), heterozygote (ID) 31, and homozygote insertion wildtype (II) 23], and those with LIS below 3 (1 DD, 9 ID, 16 II). Likewise, the frequency of the D allele was significantly less in patients with higher LIS (50% D) than lower LIS (21% D). Using these values produces a significantly higher OR of 16.0 (95% CI 1.96-130.9) for DD than for II, while the OR for ID vs. II was 2.4 (95% CI 0.9-6.4). Genotypes of the NFKB1 promoter polymorphism were associated neither with 30-day survival nor with duration of ICU stay. CONCLUSIONS: The insertion/deletion polymorphism in the promoter of NFKB1 influences the severity but not the mortality of ARDS.
OBJECTIVE: This study investigated whether the insertion/deletion polymorphism in the promoter of NFKB1 is associated with severity and/or mortality in ARDS. DESIGN AND SETTING: Prospective study in a mixed anesthesiological ICU of the University Hospital Essen. PATIENTS AND PARTICIPANTS: 103 adult patients with ARDS (white Germans). MEASUREMENTS AND RESULTS:Patients with ARDS were genotyped for the insertion/deletion polymorphism in the promoter of NFKB1 (-94ins/delATTG). In ARDSpatients genotypes differed significantly between those with severe ARDS [Lung Injury Score (LIS)>or=3; 23 homozygote deletion (DD), heterozygote (ID) 31, and homozygote insertion wildtype (II) 23], and those with LIS below 3 (1 DD, 9 ID, 16 II). Likewise, the frequency of the D allele was significantly less in patients with higher LIS (50% D) than lower LIS (21% D). Using these values produces a significantly higher OR of 16.0 (95% CI 1.96-130.9) for DD than for II, while the OR for ID vs. II was 2.4 (95% CI 0.9-6.4). Genotypes of the NFKB1 promoter polymorphism were associated neither with 30-day survival nor with duration of ICU stay. CONCLUSIONS: The insertion/deletion polymorphism in the promoter of NFKB1 influences the severity but not the mortality of ARDS.
Authors: G R Bernard; A Artigas; K L Brigham; J Carlet; K Falke; L Hudson; M Lamy; J R Legall; A Morris; R Spragg Journal: Am J Respir Crit Care Med Date: 1994-03 Impact factor: 21.405
Authors: Michael A Matthay; Guy A Zimmerman; Charles Esmon; Jahar Bhattacharya; Barry Coller; Claire M Doerschuk; Joanna Floros; Michael A Gimbrone; Eric Hoffman; Rolf D Hubmayr; Mark Leppert; Sadis Matalon; Robert Munford; Polly Parsons; Arthur S Slutsky; Kevin J Tracey; Peter Ward; Dorothy B Gail; Andrea L Harabin Journal: Am J Respir Crit Care Med Date: 2003-04-01 Impact factor: 21.405
Authors: R B Goodman; R M Strieter; D P Martin; K P Steinberg; J A Milberg; R J Maunder; S L Kunkel; A Walz; L D Hudson; T R Martin Journal: Am J Respir Crit Care Med Date: 1996-09 Impact factor: 21.405
Authors: H W Ziegler-Heitbrock; A Wedel; W Schraut; M Ströbel; P Wendelgass; T Sternsdorf; P A Bäuerle; J G Haas; G Riethmüller Journal: J Biol Chem Date: 1994-06-24 Impact factor: 5.157
Authors: Massimo Antonelli; Elie Azoulay; Marc Bonten; Jean Chastre; Giuseppe Citerio; Giorgio Conti; Daniel De Backer; François Lemaire; Herwig Gerlach; Johan Groeneveld; Goran Hedenstierna; Duncan Macrae; Jordi Mancebo; Salvatore M Maggiore; Alexandre Mebazaa; Philipp Metnitz; Jerme Pugin; Jan Wernerman; Haibo Zhang Journal: Intensive Care Med Date: 2008-01-31 Impact factor: 17.440
Authors: Ronan J MacLoughlin; Brendan D Higgins; James Devaney; Daniel O'Toole; John G Laffey; Timothy O'Brien Journal: Hum Gene Ther Date: 2015-01 Impact factor: 5.695
Authors: Meredith S Shiels; Eric A Engels; Jianxin Shi; Maria Teresa Landi; Demetrius Albanes; Nilanjan Chatterjee; Stephen J Chanock; Neil E Caporaso; Anil K Chaturvedi Journal: Cancer Date: 2012-10-08 Impact factor: 6.860
Authors: Ednan K Bajwa; Paul C Cremer; Michelle N Gong; Rihong Zhai; Li Su; B Taylor Thompson; David C Christiani Journal: PLoS One Date: 2011-05-09 Impact factor: 3.240
Authors: Jason D Christie; Mark M Wurfel; Rui Feng; Grant E O'Keefe; Jonathan Bradfield; Lorraine B Ware; David C Christiani; Carolyn S Calfee; Mitchell J Cohen; Michael Matthay; Nuala J Meyer; Cecilia Kim; Mingyao Li; Joshua Akey; Kathleen C Barnes; Jonathan Sevransky; Paul N Lanken; Addison K May; Richard Aplenc; James P Maloney; Hakon Hakonarson Journal: PLoS One Date: 2012-01-25 Impact factor: 3.240